Disc Medicine, Inc.

Alpha Score of 33 reflects weak overall profile with weak momentum, weak quality, weak sentiment. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Disc Medicine Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It targets fundamental biological pathways associated with the formation and function of red blood cells, particularly heme biosynthesis and iron homeostasis, to address unmet needs in blood disorders. The company's pipeline features bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria, X-linked protoporphyria, and Diamond-Blackfan Anemia; DISC-0974 for anemia in myelofibrosis and chronic kidney disease; and DISC-3405 for polycythemia vera and related hematologic conditions. Preclinical efforts include DISC-0998. Operating in the biotechnology sector, Disc Medicine Inc. advances innovative therapies aimed at rare and chronic blood disorders, positioning it as a key player in hematology research and patient care. Founded in 2017 and headquartered in Watertown, Massachusetts, the company emphasizes turning scientific discoveries into effective medicines.